NewAmsterdam Pharma (NASDAQ:NAMS) Director Sells $828,950.26 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Louis Lange sold 28,186 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.41, for a total transaction of $828,950.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NewAmsterdam Pharma Stock Up 1.6%

NAMS traded up $0.50 on Tuesday, hitting $31.27. The company’s stock had a trading volume of 1,016,199 shares, compared to its average volume of 840,101. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The firm has a market cap of $3.60 billion, a P/E ratio of -18.08 and a beta of 0.04. The company’s 50 day simple moving average is $33.41 and its 200-day simple moving average is $33.36.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The business had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. Equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Capital World Investors grew its position in NewAmsterdam Pharma by 17.1% in the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after acquiring an additional 1,434,986 shares in the last quarter. Jennison Associates LLC raised its position in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Duquesne Family Office LLC raised its position in NewAmsterdam Pharma by 131.2% during the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares in the last quarter. Castle Hook Partners LP bought a new stake in NewAmsterdam Pharma during the fourth quarter worth about $38,062,000. Finally, Adage Capital Partners GP L.L.C. lifted its stake in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after purchasing an additional 1,062,359 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma News Roundup

Here are the key news stories impacting NewAmsterdam Pharma this week:

• Positive Sentiment: Several sell‑side firms have raised ratings and targets (Needham raised its target to $48, HC Wainwright upgraded to strong‑buy, RBC lifted its target to $47) and the consensus remains a “Moderate Buy” with an average target near $47, supporting upside expectations.
• Positive Sentiment: Large institutional positions and recent accumulation (Capital World Investors, Jennison, Duquesne and others increased stakes) signal continuing institutional confidence and provide potential buying support under the stock.
• Neutral Sentiment: Recent profile/coverage updates (e.g., Barron’s stock page) provide visibility but do not contain new material clinical or financial news likely to immediately change fundamentals. Barron’s stock page
• Negative Sentiment: Large, repeated insider sales by CFO/insider Johannes Jacob Piete Kastelein (multiple trades on March 5–9–6 totaling several hundred thousand shares and reducing his stake by roughly ~57–60%) are material — such concentrated selling can pressure the stock and raise investor concern about insider liquidity needs or sentiment. InsiderTrades: Kastelein sales SEC filing
• Negative Sentiment: Director Louis G. Lange sold 28,186 shares (March 6), another disclosed insider sale that adds to the net insider selling narrative. SEC filing
• Negative Sentiment: Recent quarterly results (Feb. 18) showed an EPS miss and very limited revenue, with negative margins — underlying fundamentals remain loss‑making, which keeps the stock sensitive to sentiment and execution risk.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Royal Bank Of Canada lifted their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. HC Wainwright raised shares of NewAmsterdam Pharma to a “strong-buy” rating in a report on Thursday, February 19th. Finally, Stifel Nicolaus increased their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $47.10.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.